Jiangsu Recbio Technology Co., Ltd. announced that in order to meet the rapidly growing market demand for HPV 9-valent vaccines in China and the international market, after process optimization, facility upgrading and verification, the peak production capacity for the first phase of the HPV vaccine manufacturing facility of the Company will be increased to an annual output of 20 million doses of recombinant HPV 9-valent vaccine. The construction of such manufacturing facility has received technical guidance from experts of the World Health Organization ("WHO"). Upon completion, the facility will meet the requirements of China's Good Manufacturing Practices (GMP) and WHO prequalification (WHO PQ) to satisfy the global supply and demand gap of HPV 9-valent vaccines.

HPV 9-valent vaccines can prevent approximately 90% of cervical cancers and 90% of anal and genital warts, and are widely regarded as the most effective vaccines against HPV infections. At present, no domestic HPV 9-valent vaccine has been approved for sale in China. The Company's core product, HPV 9-valent vaccine REC603, is in phase III clinical stage, with a prominent advantage in total sample size and an advanced overall research and development progress.

REC603 adopts the H. polymorpha expression system to achieve high-yield and stable expression of HPV virus-like particles and to make the Company's vaccine candidate more suitable for commercial production.